Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashraf Yassen

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|February 11, 2005
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kineticsAshraf Yassen, Erik Olofsen, Albert Dahan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 1, 2012
Translational PK-PD modeling in painAshraf Yassen, Paul Passier, Yasuhisa Furuichi, et al.
Pain Medicine (Malden, Mass.)|December 12, 2017
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female SubjectsKlaus Schaffler, Ashraf Yassen, Peter Reeh, et al.
European Journal of Pain (London, England)|September 18, 2007
Morphine-6-glucuronide (M6G) for postoperative pain reliefAlbert Dahan, Eveline van Dorp, Terry Smith, et al.
Expert Opinion on Drug Safety|March 21, 2007
Naloxone treatment in opioid addiction: the risks and benefitsEveline L A van Dorp, Ashraf Yassen, Albert Dahan
Journal of Clinical Pharmacology|March 29, 2014
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young agesAshley Strougo, Ashraf Yassen, Claire Monnereau, et al.
Expert Review of Clinical Pharmacology|November 25, 2011
Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literatureChristian Martini, Erik Olofsen, Ashraf Yassen, et al.
Pharmaceutical Research|October 5, 2007
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in ratsAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2011
A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditionsAshley Strougo, Ashraf Yassen, Walter Krauwinkel, et al.
Clinical Pharmacokinetics|May 1, 2007
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphineAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|February 11, 2005
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kineticsAshraf Yassen, Erik Olofsen, Albert Dahan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 1, 2012
Translational PK-PD modeling in painAshraf Yassen, Paul Passier, Yasuhisa Furuichi, et al.
Pain Medicine (Malden, Mass.)|December 12, 2017
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase I Study of Analgesic/Antihyperalgesic Properties of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Healthy Female SubjectsKlaus Schaffler, Ashraf Yassen, Peter Reeh, et al.
European Journal of Pain (London, England)|September 18, 2007
Morphine-6-glucuronide (M6G) for postoperative pain reliefAlbert Dahan, Eveline van Dorp, Terry Smith, et al.
Expert Opinion on Drug Safety|March 21, 2007
Naloxone treatment in opioid addiction: the risks and benefitsEveline L A van Dorp, Ashraf Yassen, Albert Dahan
Journal of Clinical Pharmacology|March 29, 2014
Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young agesAshley Strougo, Ashraf Yassen, Claire Monnereau, et al.
Expert Review of Clinical Pharmacology|November 25, 2011
Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literatureChristian Martini, Erik Olofsen, Ashraf Yassen, et al.
Pharmaceutical Research|October 5, 2007
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in ratsAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2011
A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditionsAshley Strougo, Ashraf Yassen, Walter Krauwinkel, et al.
Clinical Pharmacokinetics|May 1, 2007
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphineAshraf Yassen, Erik Olofsen, Jingmin Kan, et al.
Pageof 3